Trial reportBMC anesthesiology2025
The effective dose of remimazolam in combination with sufentanil for sedation during transvaginal oocyte retrieval: an up-and-down sequential allocation trial.
Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The median effective dose (EDBMC anesthesiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe potential adverse effects of propofol on fertilization outcomes have raised concerns among patients undergoing anesthesia for oocyte retrieval. Remimazolam is a new type of ultra-short-acting benzodiazepine. This study aimed to find the effective dose of remimazolam in combination with sufentanil for sedation in oocyte retrieval.
methodsPatients aged 20 to 45 years with a BMI of 18.5 to 27.9 kg/m² and ASA physical status I or II, undergoing transvaginal oocyte retrieval, were recruited. All patients were administered intravenous sufentanil at a dose of 0.1 µg/kg, followed by intravenous remimazolam after 2 min. The initial remimazolam dose was set at 0.2 mg/kg and adjusted by 0.02 mg/kg according to the modified Dixon sequential method. The primary endpoint was successful sedation, defined as a Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score ≤ 1 and an Intraoperative Movement Scale (IOMS) score < 2 within 5 min. Adverse events were recorded. The estimation of ED50, ED90 and ED95 with a 95% confidence interval (CI) was conducted by probit regression.
resultsThe ED50, ED90 and ED95 of remimazolam for successful sedation in combination with sufentanil induction were 0.205 mg/kg (95% CI 0.190–0.222), 0.232 mg/kg (95% CI 0.218–0.311) and 0.240 mg/kg (95% CI 0.223–0.339), respectively. There were three cases of hypoxemia, with no other adverse events reported, including injection pain, hypotension, bradycardia, dizziness, nausea, vomiting, or delayed emergence.
conclusionsIn summary, when combined with 0.1 µg/kg of sufentanil, the ED50, ED90 and ED95 values of remimazolam for effective sedation during transvaginal oocyte retrieval, were 0.205 mg/kg, 0.232 mg/kg and 0.240 mg/kg, respectively, with a low occurrence of adverse events.
trial registrationThe study protocol was registered at http://www.chictr.org.cn (registration number: ChiCTR2400082576 on 01/04/2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.